首页> 外文期刊>Breast Cancer: Basic and Clinical Research >Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
【24h】

Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment

机译:癌症干细胞和类似祖细胞的药物在乳腺癌治疗中的目标

获取原文
           

摘要

The present review is focused on the current role of neoplastic stem and progenitor-like cells as primary targets in the pharmacotherapy of cancer as well as in the development of new anticancer drugs. We begin by summarizing the main characteristics of these tumor-initiating cells and key concepts that support their participation in therapeutic failure. In particular, we discuss the differences between the major carcinogenesis models (ie, clonal evolution vs cancer stem cell (CSC) model) with emphasis on breast cancer (given its importance to the study of CSCs) and their implications for the development of new treatment strategies. In addition, we describe the main ways to target these cells, including the main signaling pathways that are more activated or altered in CSCs. Finally, we provide a comprehensive compilation of the most recently tested drugs.
机译:本综述的重点是肿瘤干细胞和祖细胞样细胞作为癌症药物治疗和新抗癌药物开发中的主要靶标的当前作用。我们首先总结这些肿瘤引发细胞的主要特征以及支持其参与治疗失败的关键概念。特别是,我们讨论了主要致癌模型(即克隆进化与癌症干细胞(CSC)模型)之间的差异,重点是乳腺癌(鉴于其对CSCs的研究重要性)及其对开发新疗法的意义策略。此外,我们描述了靶向这些细胞的主要方法,包括在CSC中被激活或改变的主要信号通路。最后,我们提供了最新测试药物的全面汇编。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号